Elicio Therapeutics (ELTX)

• Market cap: $200M
• 1 day: -9.43%
• 5 days: -11.86%
• 1 month: 24%
• 3 months: 34.28%
• 6 months: -2.6%
• Year to date: 34.78%
• 1 year: 33.62%
• 5 years: -93.76%
• 10 years: -93.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Employees: 33